New Study Supports Effectiveness of RSV Immunization for Infants
New CDC data shows nirsevimab, a long-acting monoclonal antibody, was highly effective in protecting infants from RSV-associated hospitalizations. RSV is the leading cause of hospitalization among infants in the U.S. For details, read the CDC news release.
The CDC recommends — which this study...
CDC Urges Influenza, COVID-19, and RSV Vaccination Ahead of 2023-2024 Winter Season
The CDC has issued a health advisory due to low vaccination rates against influenza, COVID-19, and RSV (respiratory syncytial virus), which could lead to more severe disease and increased healthcare capacity strain in the coming weeks. Also, a recent increase in cases of multisystem inflammatory...
RSV Immunization for Infants
In response to a recent shortage of Beyfortus (Nirsevimab) — a long-acting monoclonal antibody for prevention of severe RSV among infants and children — the CDC has announced the release of 77,000 additional doses for hospitals and providers.
Nirsevimab may be given in child's 1st year. Another...
RSV Vaccine for Babies, Toddlers Now Available
Beyfortus (Nirsevimab) — a long-acting monoclonal antibody for prevention of severe respiratory syncytial virus (RSV) among infants and children — is now available for providers to order. Nirsevimab may be given in child's 1st year and then their 2nd RSV season for some high-risk patients.
MHC...Medication Updates: RSV, Postpartum Depression
RSV Vaccine for Babies, Toddlers: The FDA approved the 1st respiratory syncytial virus (RSV) vaccine for babies and toddlers. Beyfortus (nirsevimab-alip) is approved for the prevention of RSV lower respiratory tract disease in children <24 months of age who remain vulnerable to severe RSV disease...